Status:
COMPLETED
A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease
Lead Sponsor:
Teva Neuroscience, Inc.
Conditions:
Parkinson's Disease
Eligibility:
All Genders
30+ years
Phase:
PHASE4
Brief Summary
Patients with Parkinson's Disease (PD) will be divided into 2 groups at each study center at their first visit based on the drugs they are taking for their PD: * Group 1 Patients using Azilect and no...
Eligibility Criteria
Inclusion
- Idiopathic Parkinson's disease. Diagnosis previously confirmed by the presence of bradykinesia and by at least one additional cardinal sign (i.e., resting tremor, rigidity), without other known or suspected cause of parkinsonism.
- Requiring therapy for PD symptom control
- Azilect monotherapy.
- Azilect as adjunct therapy..
Exclusion
- Patients previously exposed to Azilect
- Patients with pheochromocytoma
- Concomitant MAO inhibitors or medications contraindicated for use with MAO inhibitors are not allowed.
Key Trial Info
Start Date :
October 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2007
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT00399477
Start Date
October 1 2006
End Date
July 1 2007
Last Update
April 12 2011
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.